MARKET

SRNE

SRNE

Sorrento Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.230
-0.050
-2.19%
After Hours: 2.230 0 0.00% 16:00 09/23 EDT
OPEN
2.310
PREV CLOSE
2.280
HIGH
2.390
LOW
2.220
VOLUME
576.56K
TURNOVER
--
52 WEEK HIGH
6.50
52 WEEK LOW
1.800
MARKET CAP
292.08M
P/E (TTM)
-1.0323
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SRNE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SRNE News

  • Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
  • GlobeNewswire.8h ago
  • Sorrento Therapeutics Subsidiary Scilex Files an S-1 to the SEC for its Proposed IPO
  • Benzinga.8h ago
  • Those Who Purchased Sorrento Therapeutics (NASDAQ:SRNE) Shares Three Years Ago Have A 67% Loss To Show For It
  • Simply Wall St..08/14 13:33
  • Forensic Stock Analysis For August: Do You Own These Stocks?
  • Seeking Alpha - Article.08/02 19:02

More

Industry

Biotechnology & Medical Research
-0.69%
Pharmaceuticals & Medical Research
-0.43%

Hot Stocks

Name
Price
%Change

About SRNE

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.
More

Webull offers Sorrento Therapeutics Inc (SRNE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.